Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-09-30
2008-03-04
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C514S012200, C530S330000, C530S331000
Reexamination Certificate
active
07338939
ABSTRACT:
The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by circuitous routes such as intravenous (“shooting”) injection and intranasal administration (“snorting”). Further, hydrocodone compositions of the invention are resistant to oral abuse as well, since release of the hydrocodone at suprapharmacological doses reaches saturation.
REFERENCES:
patent: 3843696 (1974-10-01), Wagner et al.
patent: 3846399 (1974-11-01), Hirschmann et al.
patent: 3878187 (1975-04-01), Schneider et al.
patent: 3884898 (1975-05-01), Schneider
patent: 3975342 (1976-08-01), Gross
patent: 3998799 (1976-12-01), Bodor et al.
patent: 4025501 (1977-05-01), Leute
patent: 4040907 (1977-08-01), Ullman et al.
patent: 4346166 (1982-08-01), Montag et al.
patent: 4356166 (1982-10-01), Peterson et al.
patent: 4399121 (1983-08-01), Albarella et al.
patent: 4427660 (1984-01-01), Schiffman et al.
patent: 4457907 (1984-07-01), Porter
patent: 4552864 (1985-11-01), Antoni et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4801575 (1989-01-01), Pardridge
patent: 4863735 (1989-09-01), Kohn et al.
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 4960790 (1990-10-01), Stella et al.
patent: 4976962 (1990-12-01), Bichon et al.
patent: 5026827 (1991-06-01), Miyazaki
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5183883 (1993-02-01), Tanaka et al.
patent: 5219564 (1993-06-01), Zalipsky et al.
patent: 5238714 (1993-08-01), Wallace et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5534496 (1996-07-01), Lee et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5762909 (1998-06-01), Uzgiris
patent: 5767227 (1998-06-01), Latham et al.
patent: 5846743 (1998-12-01), Janmey et al.
patent: 5851536 (1998-12-01), Yager et al.
patent: 5882645 (1999-03-01), Toth et al.
patent: 5891459 (1999-04-01), Cooke et al.
patent: 5898033 (1999-04-01), Swadesh et al.
patent: 5910569 (1999-06-01), Latham et al.
patent: 5948750 (1999-09-01), Garsky et al.
patent: 5952294 (1999-09-01), Lazo et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 6005004 (1999-12-01), Katz et al.
patent: 6030941 (2000-02-01), Summerton et al.
patent: 6043230 (2000-03-01), Arimilli et al.
patent: 6048736 (2000-04-01), Kosak
patent: 6074659 (2000-06-01), Kunz et al.
patent: 6075120 (2000-06-01), Cheronis et al.
patent: 6093391 (2000-07-01), Kabanov et al.
patent: 6235718 (2001-05-01), Balasubramanium
patent: 6255285 (2001-07-01), Kotake
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: 6458842 (2002-10-01), Dickinson et al.
patent: 6716452 (2004-04-01), Piccariello et al.
patent: 6740641 (2004-05-01), Gao
patent: 6784186 (2004-08-01), Jackson
patent: 7060708 (2006-06-01), Piccariello et al.
patent: 2001/0031873 (2001-10-01), Greenwald et al.
patent: 2002/0059013 (2002-05-01), Rajala et al.
patent: 2002/0098999 (2002-07-01), Gallop et al.
patent: 2002/0099013 (2002-07-01), Piccariello et al.
patent: 2002/0151526 (2002-10-01), Gallop et al.
patent: 2002/0151529 (2002-10-01), Cundy et al.
patent: 2004/0204434 (2004-10-01), Shafer
patent: 2005/0038121 (2005-02-01), Mickle et al.
patent: 2005/0054561 (2005-03-01), Mickle et al.
patent: 2005/0065086 (2005-03-01), Mickle et al.
patent: 2005/0069550 (2005-03-01), Mickle et al.
patent: 2005/0080012 (2005-04-01), Mickle et al.
patent: 2005/0176644 (2005-08-01), Mickle et al.
patent: 2005/0176645 (2005-08-01), Mickle et al.
patent: 2005/0176646 (2005-08-01), Mickle et al.
patent: 2005/0266070 (2005-12-01), Mickle et al.
patent: 2006/0014697 (2006-01-01), Mickle et al.
patent: 0 187 547 (1987-07-01), None
patent: WO 94/11021 (1994-05-01), None
patent: WO 95/12605 (1995-05-01), None
patent: WO 95/14033 (1995-05-01), None
patent: WO 97/36616 (1997-10-01), None
patent: WO 08/04277 (1998-02-01), None
patent: WO 98/04277 (1998-02-01), None
patent: WO 00/37103 (2000-06-01), None
patent: WO 02/34237 (2002-05-01), None
Aggarwal, et al., “Synthesis and Biological Evaluation of Prodrugs of Zidovudine,”J. Med. Chem., 33(5):1505-1511 (1990).
Amidon, G., et al., “A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability,”Pharmaceutical Research, vol. 12, No. 3 (1995).
Amidon, G.L., et al., “5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT are Absorbed by the Intestinal PEPT1 Peptide Transporter,”Pharm Res, 16(2):175 (1999), Abstract.
Balimane, P., et al., “Effect of Ionization on the Variable Uptake of Valacyclovir via the Human Intestinal Peptide Transporter (hPepT1) in CHP cells,”Biopharm Drug Dispos, 21(5):165-174 (2000), Abstract.
Balimane, P.V., et al., “Direct Evidence for Peptide Transporter (PepT1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir,”Biochem Biophys Res Commun, 250(2):246-251 (1998), Abstract.
Bunevicius, R., “Effects of Thyroxine as Compared with Thyroxine Plus Triiodothyronine in Patients with Hypothyroidism,”The New England Journal of Medicine, vol. 340, No. 6 (1999).
Burnette, Thimysta C., et al., “Metabolic Disposition of the Acyclovir Prodrug Valaciclovir in the Rat,”Drug Metabolism and Disposition, 22(1):60-64 (1994).
Canaris, G., “The Colorado Thyroid Disease Prevalence Study,” Archives Internal Medicine Articles and Abstracts, vol. 160, No. 4 (2000).
De Vrueh, Remco L.A., et al, “Transport of L-Valine-Acyclovir Via the Oligopeptide Transporter in the Human Intestinal Cell Line, Caco-2,”Journal of Pharmacology and Experimental Therapeutics, 286(2):1166-1170 (1988).
Friedrichsen, G.M., et al., “Model Prodrugs Designed for the Intestinal Peptide Transporter. A Synthetic Approach for Coupling of Hydroxy-Containing Compounds to Dipeptides,”Eur J Pharm Sci, 14(1):13-19 (2001, Abstract.
Guo, A., et al., “Interactions of a Nonpeptidic Drug, Valacyclovir, with the Human Intestinal Peptide Transporter (hPEPT1) Expressed in a Mammalian Cell Line,”Pharmacol Exp Ther, 289(1):448-454 (1999), Abstract.
Han H., et al., “5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT and Absorbed by the Intestinal PEPT1 Peotide Transporter,”Pharm Res, 15(8): 1154-1159 (1998), Abstract.
Han, H.K., et al., “Cellular Uptake Mechanism of Amino Acid Ester prodrugs in Caco-2hPEPT1 Cells Overexpressing a Human Peptide Transporter,”Pharm Res, 15(9):1382-1386 (1998), Abstract.
Han, Hyo-Kyung, et al., “Targeted Prodrug Design to Optimize Drug Delivery,”AAPS PharmSci, 2(1): Article 6 (2000).
Havranova, Marie et al., “A High-Molecular Mass Derivative of Trypsin-Kallikrein Inhibitor for Potential Medical Use, II,”Hoppe-Seyler's Z. Physiol. Chem., 363:295-303 (1982).
Herrera-Ruiz, D., et al., “Spatial Expression Patterns of Peptide Transporters in the Human and Rat Gastrointestinal Tracts, Carco-2 in vitro Cell Culture Model, and Multiple Human Tissues,”AAPS PharmSci,3(1):E9 (2001), Abstract.
Hosztafi, S. et al. “Synthesis and Analgetic Activity of Nicotinic Esters of Morphine Derivatives,” Arzneim.-Forsch./Drug Res. 43(II), Nr. 11 (1993).
International Search Report, dated Oct. 9, 2003, for PCT/US03/05525.
International Search Report, dated Sep. 3. 2003.
Knutter, I, et al., “A Novel Inhibitor of the Mammalian Peptide Transporter PEPT1,”Biochemistry40(14):4454-4458 (2001), Abstract.
Kovacs, J., et al., “Glutamic and Aspartic Anhydrides. Rearrangement/of N-Carboxyglutamic 1,5-Anhydride to the Leuchs' Anhydride and Conversion of the Latter to Pyroglutamic Acid,”.
Kramer, Werner et al., “Intestinal Absorption of Peptides by Coupling to Bile
Krishnan Suma
Lauderback Christopher
Mickle Travis
Miller Christal
Moncrief James Scott
Audet Maury
Darby & Darby P.C.
New River Pharmaceuticals Inc.
Tsang Cecilia J.
LandOfFree
Abuse-resistant hydrocodone compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Abuse-resistant hydrocodone compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Abuse-resistant hydrocodone compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3975679